Spots Global Cancer Trial Database for Paricalcitol in Treating Patients With Myelodysplastic Syndrome
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Paricalcitol in Treating Patients With Myelodysplastic Syndrome
Official Title: A Phase II Trial Of Paricalcitol In Myelodysplastic Syndromes
Study ID: NCT00064376
Interventions
Study Description
Brief Summary: RATIONALE: Paricalcitol is a form of vitamin D that may help myelodysplastic cells develop into normal bone marrow cells. PURPOSE: Phase II trial to study the effectiveness of paricalcitol in treating patients who have myelodysplastic syndrome.
Detailed Description: OBJECTIVES: * Determine the clinical effects of paricalcitol in patients with myelodysplastic syndromes. * Determine whether this drug can improve RBC, WBC, or platelet counts in these patients. * Determine whether this drug can decrease the risk of development of leukemia without causing undue toxicity in these patients. OUTLINE: Patients receive oral paricalcitol daily for 4 months in the absence of disease progression or unacceptable toxicity. Patients are followed at 1 month. PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study within 8 months.
Keywords
Eligibility
Minimum Age: 25 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles, California, United States
Contact Details
Name: H. Phillip Koeffler, MD
Affiliation: Cedars-Sinai Medical Center
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
